Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00058305 | Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2013 | clinicaltrials |
| NCT00891072 | Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2013 |
| clinicaltrials |
| NCT00017381 | Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma | completed | Early Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00335348 | Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse | completed | Phase 2 | 101 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00022581 | Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00118170 | Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function | completed | Phase 1 | 150 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00124605 | Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00253578 | Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00142181 | Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia | completed | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 21, 2012 | clinicaltrials |
| NCT00882063 | Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 19 | Piramal Enterprises LimitedINDUSTRY | 1 | Nov 21, 2012 | clinicaltrials |
| NCT00513175 | Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia | completed | — | 44 | University of California, San FranciscoOTHER | 1 | Nov 9, 2012 | clinicaltrials |
| NCT00366275 | Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma | completed | Phase 2 | 64 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00012350 | Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma | completed | Phase 2 | 44 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 23, 2012 | clinicaltrials |
| NCT01409148 | Radioimmunoimaging of AL Amyloidosis | completed | Phase 1 | 38 | University of TennesseeOTHER | 1 | Oct 11, 2012 | clinicaltrials |
| NCT00920855 | Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | CephalonINDUSTRY | 1 | Oct 4, 2012 | clinicaltrials |
| NCT01700608 | Prospective Observational Study on Plerixafor After Chemotherapy | completed | — | 27 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 4, 2012 | clinicaltrials |
| NCT01054781 | Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL) | completed | Phase 2 | 91 | Samsung Medical CenterOTHER | 1 | Sep 27, 2012 | clinicaltrials |
| NCT00992134 | Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma | completed | Phase 2 | 41 | St. Bortolo HospitalOTHER | 1 | Sep 26, 2012 | clinicaltrials |
| NCT00005624 | CI-994 in Treating Patients With Advanced Myeloma | completed | Phase 2 | 6 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 25, 2012 | clinicaltrials |
| NCT01198457 | Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment(BONA) | completed | — | 147 | BayerINDUSTRY | 1 | Sep 7, 2012 | clinicaltrials |
| NCT00710528 | Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 192 | Gilead SciencesINDUSTRY | 1 | Aug 31, 2012 | clinicaltrials |
| NCT00146055 | Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood | completed | Phase 2 | 60 | University of Michigan Rogel Cancer CenterOTHER | 1 | Aug 9, 2012 | clinicaltrials |
| NCT00067639 | Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00822432 | Coproporphyrine Isomers and Methotrexate Elimination(COMETH) | completed | — | 85 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 31, 2012 | clinicaltrials |
| NCT00303199 | Study of ZIO-101 in Multiple Myeloma | completed | Phase 1 / Phase 2 | 35 | Alaunos TherapeuticsINDUSTRY | 2 | Jul 19, 2012 | clinicaltrials |
| NCT00592046 | A Phase I Trial of ZIO-101 in Hematologic Cancers | completed | Phase 1 | 12 | Alaunos TherapeuticsINDUSTRY | 1 | Jul 19, 2012 | clinicaltrials |
| NCT00476294 | Long-Term Follow Up Study for AMD3100 Patients | completed | — | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 11, 2012 | clinicaltrials |
| NCT00415064 | Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma | completed | Phase 1 | 32 | AEterna ZentarisINDUSTRY | 1 | Jul 6, 2012 | clinicaltrials |
| NCT00925821 | Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 146 | Wuerzburg University HospitalOTHER | 1 | Jun 28, 2012 | clinicaltrials |
| NCT00660166 | Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions | completed | Phase 1 | 13 | Tufts Medical CenterOTHER | 1 | Jun 27, 2012 | clinicaltrials |
| NCT01524445 | Retrospective Survey of Re-treatment With Bortezomib | completed | — | 35 | Janssen Pharmaceutica N.V., BelgiumINDUSTRY | 1 | Jun 12, 2012 | clinicaltrials |
| NCT00427557 | Cellular Therapy With Cord Blood Cells | completed | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2012 | clinicaltrials |
| NCT00420849 | A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 587 | Celgene CorporationINDUSTRY | 5 | May 21, 2012 | clinicaltrials |
| NCT00234169 | A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone | completed | Phase 1 / Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 10, 2012 | clinicaltrials |
| NCT00514475 | Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma | completed | Phase 2 | 160 | Oslo University HospitalOTHER | 1 | May 4, 2012 | clinicaltrials |
| NCT01263899 | A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies | completed | Phase 2 | 28 | S*BIOINDUSTRY | 2 | Apr 20, 2012 | clinicaltrials |
| NCT00089453 | Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant | completed | Phase 1 | 10 | University of ArkansasOTHER | 1 | Apr 19, 2012 | clinicaltrials |
| NCT01006070 | Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine | completed | — | 50 | University of California, San FranciscoOTHER | 1 | Mar 21, 2012 | clinicaltrials |
| NCT00333190 | CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation | completed | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 16, 2012 | clinicaltrials |
| NCT00799461 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | completed | Phase 3 | 1,337 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | Mar 7, 2012 | clinicaltrials |
| NCT00116961 | Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma | completed | Phase 2 | 40 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 7, 2012 | clinicaltrials |
| NCT00135187 | Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma | completed | N/A | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 7, 2012 | clinicaltrials |
| NCT00029224 | Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions | completed | Phase 4 | 500 | NovartisINDUSTRY | 1 | Feb 1, 2012 | clinicaltrials |
| NCT00608907 | An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) | completed | Phase 1 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jan 30, 2012 | clinicaltrials |
| NCT00531453 | A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 98 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00427765 | Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma | completed | Phase 2 | 168 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 19, 2012 | clinicaltrials |
| NCT00048230 | PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 620 | Millennium Pharmaceuticals, Inc.INDUSTRY | 13 | Jan 13, 2012 | clinicaltrials |
| NCT00063726 | A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 | completed | Phase 3 | 600 | Millennium Pharmaceuticals, Inc.INDUSTRY | 13 | Jan 13, 2012 | clinicaltrials |
| NCT00636792 | A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma(VERTICAL) | completed | Phase 2 | 73 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 13, 2012 | clinicaltrials |
| NCT00505232 | Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)(LCM-04-02) | completed | Phase 2 | 30 | CABYCINDUSTRY | 1 | Jan 2, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Jan 10, 2013source: clinicaltrials